Lu 29-252

Lu 29-252

Clinical data
Other names	Lu-29-252; LU-29252; LU29252; Lu 29–252
Drug class	Sigma σ2 receptor ligand
Identifiers
IUPAC name 1'-(4-spiro[1H-2-benzofuran-3,4'-piperidine]-1'-ylbutyl)spiro[1H-2-benzofuran-3,4'-piperidine]
PubChem CID	18700226
PubChem SID	272800362
Chemical and physical data
Formula	C28H36N2O2
Molar mass	432.608 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCC12C3=CC=CC=C3CO2)CCCCN4CCC5(CC4)C6=CC=CC=C6CO5
InChI InChI=1S/C28H36N2O2/c1-3-9-25-23(7-1)21-31-27(25)11-17-29(18-12-27)15-5-6-16-30-19-13-28(14-20-30)26-10-4-2-8-24(26)22-32-28/h1-4,7-10H,5-6,11-22H2 Key:AEUZWXWBBOOYMB-UHFFFAOYSA-N

Lu 29-252 is a selective sigma σ₂ receptor ligand which was under development for the treatment of anxiety disorders but was never marketed.^{[1][2][3][4][5]} It reached the preclinical stage of development prior to the discontinuation of its development.^[1] The drug was under development by Lundbeck.^[1]

References

1. "LU 29252". AdisInsight. Springer Nature Switzerland AG. 23 May 1995. Retrieved 22 October 2024.
2. "LU-29252". Therapeutic Target Database (TTD). D0T8HU. Retrieved 22 October 2024.
3. Gronier B, Debonnel G (March 1999). "Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems". European Journal of Pharmacology. 368 (2–3): 183–196. doi:10.1016/s0014-2999(99)00025-4. PMID 10193654.
4. Abaimov DA, Kovalev GI (2011). "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal. 5 (2). Pleiades Publishing Ltd: 83–91. doi:10.1134/s1819712411010028. ISSN 1819-7124.
5. Rousseaux CG, Greene SF (August 2016). "Sigma receptors [σRs]: biology in normal and diseased states". Journal of Receptor and Signal Transduction Research. 36 (4): 327–388. doi:10.3109/10799893.2015.1015737. PMC 4906365. PMID 26056947.